Navamedic ASA: Amended cash offer to acquire Sensidose AB and acquisition of shares in Sensidose AB

Publisert: 22.04.2023

Navamedic ASA: Recommended cash offer to acquire Sensidose for approximately SEK 75 million

Publisert: 29.03.2023

Navamedic ASA: Q4 2022 financial results

Publisert: 16.02.2023

Navamedic ASA: Invitation to 2022 4th quarter presentation

Publisert: 13.02.2023

Navamedic ASA acquires innovative antibiotic product for hospital use in the Nordic region

Publisert: 23.11.2022

Navamedic ASA: Q3 2022 financial results

Publisert: 01.11.2022